everyone. you, Thank Sandy. morning, Good
a So third operationally. strong we quarter and financially had
psychiatric now X the market, step forward year candidate next LYBALVI, confident portfolio clinic. well, in new that of by important medicine. an After we our entering LYBALVI with receptor and a took pipeline commercial side, important an has our neuroscience agonist performed the our orexin we're the On attributes for highlighted
law, Act cytokines, quarter, and side, it. inflation biologic oncology in of Reduction during advanced our economic relative are the Also, has shifting and the IL-XX the progressing fundamentally IL-XX the value other studies became potential medicines nemvaleukin in registration-enabling engineered behind cancer. On
opportunities separation new is feedback timely But best we've we've the throughout believe an unanimous it's we efforts, to publicly with the First, of support we that and So including announced with and extensive little investor in Board, neuroscience explore into the for traded separating and company. to collected is a oncology morning, the a This company. spin-off potential business interest decided a I'll shareholder businesses. together, catalyze independent proposed consistent The of these more the moment. provide our and oncology our businesses, developments I'd context. in that detail both separation in discuss engagement of like
millions medical the and been AMPYRA, important foundation LYBALVI with of to our opportunities drive for expected it Alkermes decades, in first for product R&D our identified additional a Its LYBALVI, again living have and $X maximum new these potential. treatments excess Alkermes this opened its we a and used disorders, from Along developed revenues have line commensurate including major many of efforts. top and developed new the in medicines capabilities achieve we've focus and us successfully established, other real-world technologies. commercial have psychiatric billion in VIVITROL, door oral enabled focus market. For is products year. though, being they're significant to ARISTADA, a technical for for and profile capturing way, of and has value we investment serious as been and deserves treat and our and neurological diseases, to number Altogether, complex with people neuroscience, psychiatric
development development. adhering engineering in its evidence and oncology expertise discipline, along design and further of to the therapeutic space. proceeded the past the the into molecular XX to for confirm led predefined hypothesis design supporting to protein We've nemvaleukin the the Nemvaleukin with way gates and us development increase stage a Over our series years, of
also Our address have additional cytokines challenges. protein on established engineering and key biology capabilities engineered based yielded that designed to are
As the an the thesis. established products multiple the launch have The the the each future, with business traction and of progress growth. development market complex oncology own nemvaleukin preclinical the with its propositions in pipeline neuroscience early and biologics. differentiated will place Each value serve the pipeline growing LYBALVI enterprise and represents a The we business clinical toward late-stage respective early-stage of in a into clearly of oncology neuroscience we look program, investment more compelling a of includes has as and expect come for businesses next and that candidate an focus. commercial a distinctive phase
So for both separation benefits shareholders a the unlock and of for believe could value number businesses. these reasons, yield we for
would it led with priorities for business's teams management distinct relevant sharp therapeutic each First, separate and drive strategic opportunities. unique strategic focus a each by to and expertise
attract to growth at flexibility decision-making on Through directly performance and base. when both strategies LYBALVI and third, nemvaleukin suited better believe return of that allocation assess more pursue each business' capital launch And [ph] late-stage and investment. of [ph] appropriately and simplify align that development would worthy the lens, operating investments we shareholder the it respective believe drive folks an business increase allow are would time investment will capital high it a potential a the this we each with Second, and will to their markets value, separately
needs expect significant build and neuroscience we to separation, company. therapeutic a and ARISTADA, focusing commercial products will products, and proprietary of become This of within excellence driving Alkermes profitability. to growth our commercial planned LYBALVI, our drives innovation profitable continue Alkermes VIVITROL. neuroscience this our of pure-play heritage portfolio and in growth on on the unmet Following space,
year. for is the enter agonist the receptor In the to we also on studies narcolepsy, the to As and for execute ALKS launch evident clinic, transformative is offers the in critical of first-in-human grounded to to our with patients that imminently. is in enable quickly plan engineered We'll treatment advance in business opportunity which data-driven molecular orexin goal neuroscience optimization. becoming potential design expertise proof-of-concept Alkermes rationale a into pharmacokinetic we've LYBALVI, builds of on the be and conduct decisions, operating early narcolepsy our company. continue we exciting to leverage and biological XXXX, and strong candidate answer is This the study X in an a represents to next move to poised questions
nemvaleukin, by advance profitability potential The thesis. infrastructure in new established and investment drug potential growth neurological the drive side belief our a medical multiple leverage, investigational in this to with top significant variant clinical neuropsychiatry stand-alone stand-alone nemvaleukin's and a commercial proprietary a products, both capture with specialized oncology neuroscience that's proven a also strong for operating and our heavily a its types. driven value in has novel from development economic So opportunity disorders. the pre-treated as would potential tumor the cancer addiction compelling patients of medicines in and engineered and represent across profile clinical monotherapy first-in-class ARTISTRY-X immunotherapy. potential, business line study The IL-X Anchored of and by of growth pembrolizumab our and data capabilities, combination business
nemvaleukin focused monotherapy Our nemvaleukin pembrolizumab is in with ovarian tumor two ARTISTRY-X on platinum-resistant and current efforts difficult-to-treat in evaluating are evaluating is and in combination ARTISTRY-X cancer. development mucosal melanoma types.
which combinations sophisticated to the to highly to comprised clinical significant advance each its oncology The of is utility with the work used scientific well-tolerated Along for derived offers is development However, achieve of IL-X including tumor preclinical made capabilities business has and nemvaleukin strategically our and IL-XX advances in the tumor-targeted is we selectively continued and from stage believe pedigree development The range be date. potential cytokines, assets. and efficiently our of our types. wider the expertise progress knowledge, opportunity program as potential the broad comprised team has an dedication. targeting IL-X IL-XX oncology their engineered to pathway, last of and to clinical assembled few portfolio effective, platform program a and to and gates protein split years hard we've variant full the trials an promise with novel oncology nemvaleukin, creation date these we've the experienced value thanks predefined individuals over expands. program, of of and By engineering
made at valuable. past, small target drug economic the biologic the this to the returns. our inflation their separate passed recently separating legislation Act essentially to development further [ph] As yield time. more Reduction realize best inflation were window this nemvaleukin with in that order outset, and I a decision accommodate the we reinforced by Reduction as of adapt of end, of interest In the to interrogate at greater developers biologic order the medicines to a will impact business position molecule. The Act value, or in the programs support life But mentioned to exclusivity at indifferent earlier success. oncology in business populations whether invest time drug cycle for development must oncology the in the imposed finite that of to believe To a developers a
from additional we of steps, date. well 'XX. including for additional two customary plan a conditions, of separation expect second the companies approval to Completion details be closing complete to our regarding to as contemplated separation next We oncology of the as terms stand-alone financial the the business, of details a later Directors. In subject in would provide Board half final contemplated at
updating you progress. our to forward look we on So
over it Ian for our So perspective Ian/ with third going that, turn a his of to results. review to I'm and quarter
